tradingkey.logo

Unicycive Updates NDA for Oxylanthanum Carbonate to Treat CKD-Related Hyperphosphatemia

ReutersJun 10, 2025 10:32 AM

- Unicycive Therapeutics Inc UNCY.O:

  • UNICYCIVE PROVIDES UPDATE ON NEW DRUG APPLICATION FOR OXYLANTHANUM CARBONATE TO TREAT HYPERPHOSPHATEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS

  • UNICYCIVE THERAPEUTICS INC - FDA FINAL DECISION ON OLC NDA EXPECTED BY JUNE 28, 2025

  • UNICYCIVE THERAPEUTICS INC - FDA IDENTIFIES DEFICIENCIES AT THIRD-PARTY MANUFACTURING VENDOR

  • UNICYCIVE THERAPEUTICS INC - FDA IDENTIFIES CGMP COMPLIANCE DEFICIENCIES AT THIRD-PARTY VENDOR

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI